Abstract
EC: “the applicant shall not be required to provide the results of pharmacological and toxicological tests or the results of clinical trials if he can demonstrate: (i) either that the proprietary medicinal product is essentially similar to a product authorized … and that the person responsible for the marketing of the original product has consented to the … references contained in the file being used … (ii) or by detailed references to published scientific literature … (iii) or that the product is essentially similar to a product which has been authorized within the Community … for not less than 6 (10) years and is marketed in the Member State for which the application is made …; … where the … product is intended for a different therapeutic use from that of the other products marketed or is to be administered by different routes or doses, the results of appropriate pharmacological and toxicological tests and/ or clinical trials must be provided”; → see also hybrid procedure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag/Wien
About this chapter
Cite this chapter
Nahler, G. (2009). abriged application. In: Dictionary of Pharmaceutical Medicine. Springer, Vienna. https://doi.org/10.1007/978-3-211-89836-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-211-89836-9_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-89835-2
Online ISBN: 978-3-211-89836-9
eBook Packages: MedicineMedicine (R0)